Skip to main content
  1. Metz SW, Thomas A, Brackbill A, et al. Oligomeric state of the ZIKV E protein defines protective immune responses. Nat Commun. 2019;10(1):4606. Published 2019 Oct 10. doi:10.1038/s41467-019-12677-6
  2. Gallichotte EN, Young EF, Baric TJ, et al. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing AntibodiesMBio. 2019;10(5):e01485-19. Published 2019 Sep 17. doi:10.1128/mBio.01485-19
  3. Grifoni A, Moore E, Voic H, et al. Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell ResponsesFront Immunol. 2019;10:1568. Published 2019 Jul 5. doi:10.3389/fimmu.2019.01568
  4. Collins MH, Tu HA, Gimblet-Ochieng C, et al. Human antibody response to Zika targets type-specific quaternary structure epitopes. JCI Insight. 2019;4(8):e124588. Published 2019 Apr 18. doi:10.1172/jci.insight.124588
  5. Swanstrom JA, Nivarthi UK, Patel B, et al. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. J Infect Dis. 2019;220(2):219–227. doi:10.1093/infdis/jiz109
  6. Nivarthi UK, Tu HA, Delacruz MJ, et al. Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection modelEBioMedicine. 2019;41:465–478. doi:10.1016/j.ebiom.2019.02.060
  7. Andrade P, Gimblet-Ochieng C, Modirian F, et al. Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. Nat Commun. 2019;10(1):938. Published 2019 Feb 26. doi:10.1038/s41467-019-08845-3
  8. Raut R, Corbett KS, Tennekoon RN, et al. Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies. Proc Natl Acad Sci U S A. 2019;116(1):227–232. doi:10.1073/pnas.1812055115
  1. Grifoni A, Costa-Ramos P, Pham J, et al. Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8+ T Cells. J Immunol. 2018;201(12):3487–3491. doi:10.4049/jimmunol.1801090
  2. Gallichotte EN, Baric TJ, Nivarthi U, et al. Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and NeutralizationCell Rep. 2018;25(5):1214–1224. doi:10.1016/j.celrep.2018.10.006
  3. Metz SW, Thomas A, Brackbill A, et al. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype. PLoS Negl Trop Dis. 2018;12(9):e0006793. Published 2018 Sep 24. doi:10.1371/journal.pntd.0006793
  4. Willcox AC, Collins MH, Jadi R, et al. Seroepidemiology of Dengue, Zika, and Yellow Fever Viruses among Children in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2018;99(3):756–763. doi:10.4269/ajtmh.18-0156
  5. de Silva A.M., Rey F.A., Young P.R., Hilgenfeld R., Vasudevan S.G. (2018) Viral Entry and NS1 as Potential Antiviral Drug Targets. In: Hilgenfeld R., Vasudevan S. (eds) Dengue and Zika: Control and Antiviral Treatment Strategies. Advances in Experimental Medicine and Biology, vol 1062. Springer, Singapore
  6. Gallichotte E.N., Baric R.S., de Silva A.M. (2018) The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections. In: Hilgenfeld R., Vasudevan S. (eds) Dengue and Zika: Control and Antiviral Treatment Strategies. Advances in Experimental Medicine and Biology, vol 1062. Springer, Singapore
  7. Swanstrom JA, Henein S, Plante JA, et al. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate. J Infect Dis. 2018;217(12):1932–1941. doi:10.1093/infdis/jiy063
  8. Kudlacek ST, Premkumar L, Metz SW, et al. Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins. J Biol Chem. 2018;293(23):8922–8933. doi:10.1074/jbc.RA118.002658
  9. Montoya M, Collins M, Dejnirattisai W, et al. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the AmericasJ Infect Dis. 2018;218(4):536–545. doi:10.1093/infdis/jiy164
  10. Metz SW, Thomas A, White L, et al. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol J. 2018;15(1):60. Published 2018 Apr 2. doi:10.1186/s12985-018-0970-2
  11. G.D. Gromowski, S. Henein, C.B. Kannadka, et al. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine Vaccine, 36 (2018), pp. 2403-2410

  12. Gallichotte EN, Baric TJ, Yount BL Jr, et al. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathog. 2018;14(2):e1006934. Published 2018 Feb 26. doi:10.1371/journal.ppat.1006934
  13. Ramasamy V, Arora U, Shukla R, et al. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. PLoS Negl Trop Dis. 2018;12(1):e0006191. Published 2018 Jan 8. doi:10.1371/journal.pntd.0006191
  14. Goncalves A, Peeling RW, Chu MC, et al. Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report. J Infect Dis. 2018;217(7):1060–1068. doi:10.1093/infdis/jix678
  15. Premkumar L, Collins M, Graham S, et al. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus InfectionJ Clin Microbiol. 2018;56(3):e01504-17. Published 2018 Feb 22. doi:10.1128/JCM.01504-17
  1. Widman DG, Young E, Nivarthi U, et al. Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4Sci Rep. 2017;7(1):17169. Published 2017 Dec 7. doi:10.1038/s41598-017-17355-5
  2. Liu P, Weinreb V, Ridilla M, et al. Rapid, directed transport of DC-SIGN clusters in the plasma membraneSci Adv. 2017;3(11):eaao1616. Published 2017 Nov 8. doi:10.1126/sciadv.aao1616
  3. Grifoni A, Angelo MA, Lopez B, et al. Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic AreasFront Immunol. 2017;8:1309. Published 2017 Oct 13. doi:10.3389/fimmu.2017.01309
  4. Grifoni A, Pham J, Sidney J, et al. Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. J Virol. 2017;91(24):e01469-17. Published 2017 Nov 30. doi:10.1128/JVI.01469-17
  5. Andrade DV, Katzelnick LC, Widman DG, et al. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific EpitopesMBio. 2017;8(5):e01205-17. Published 2017 Sep 19. doi:10.1128/mBio.01205-17
  6. de Silva AM, Harris E. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. Cold Spring Harb Perspect Biol. 2018;10(6):a029371. Published 2018 Jun 1. doi:10.1101/cshperspect.a029371
  7. Metz SW, Gallichotte EN, Brackbill A, et al. In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers. Sci Rep. 2017;7(1):4524. Published 2017 Jul 3. doi:10.1038/s41598-017-04767-6
  8. Reller ME, de Silva AM, Miles JJ, et al. Unsuspected Dengue as a Cause of Acute Febrile Illness in Children and Adults in Western Nicaragua. PLoS Negl Trop Dis. 2016;10(10):e0005026. Published 2016 Oct 28. doi:10.1371/journal.pntd.0005026
  9. Patel B, Longo P, Miley MJ, Montoya M, Harris E, de Silva AM. Dissecting the human serum antibody response to secondary dengue virus infectionsPLoS Negl Trop Dis. 2017;11(5):e0005554. Published 2017 May 15. doi:10.1371/journal.pntd.0005554
  10. Collins MH, McGowan E, Jadi R, et al. Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. Emerg Infect Dis. 2017;23(5):773–781. doi:10.3201/eid2305.161630
  11. Gallichotte EN, Menachery VD, Yount BL Jr, et al. Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone. mSphere. 2017;2(1):e00380-16. Published 2017 Feb 22. doi:10.1128/mSphere.00380-16
  12. Nivarthi UK, Kose N, Sapparapu G, et al. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and VaccinationJ Virol. 2017;91(5):e02041-16. Published 2017 Feb 14. doi:10.1128/JVI.02041-16
  13. Henein S, Swanstrom J, Byers AM, et al. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals. J Infect Dis. 2017;215(3):351–358. doi:10.1093/infdis/jiw576

 

  1. Metz SW, Tian S, Hoekstra G, et al. Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses. PLoS Negl Trop Dis. 2016;10(10):e0005071. Published 2016 Oct 20. doi:10.1371/journal.pntd.0005071
  2. de Silva AM. Ticks Take Cues from Mammalian Interferon. Cell Host & Microbe. 2016;20(1):3-4. Published 2016 Jul 13. doi:10.1016/j.chom.2016.06.016
  3. Lazear HM, Stringer EM, de Silva AM. The Emerging Zika Virus Epidemic in the AmericasResearch Priorities. JAMA. 2016;315(18):1945–1946. doi:10.1001/jama.2016.2899

  4. Messer WB, Yount BL, Royal SR, et al. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. J Virol. 2016;90(10):5090–5097. Published 2016 Apr 29. doi:10.1128/JVI.00155-16
  5. Smith SA, Nivarthi UK, de Alwis R, et al. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site. J Virol. 2015;90(2):780–789. Published 2015 Oct 28. doi:10.1128/JVI.01805-15
  6. Callaway JB, Smith SA, Widman DG, et al. Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model. PLoS One. 2015;10(8):e0136708. Published 2015 Aug 24. doi:10.1371/journal.pone.0136708
  7. Weiskopf D, Bangs DJ, Sidney J, et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci U S A. 2015;112(31):E4256–E4263. doi:10.1073/pnas.1505956112
  8. Fibriansah G, Ibarra KD, Ng TS, et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015;349(6243):88–91. doi:10.1126/science.aaa8651
  9. Callaway JB, Smith SA, McKinnon KP, de Silva AM, Crowe JE Jr, Ting JP. Spleen Tyrosine Kinase (Syk) Mediates IL-1β Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection. J Biol Chem. 2015;290(28):17306–17320. doi:10.1074/jbc.M115.664136
  10. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE Jr, de Silva AM, Baric RS (2015)           A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. MBio. 6(5)
  11. Fibriansah G, Ibarra K, Ng T-S, Smith S, Tan J, Lim, Kostyuchenko VA, Wang, de Silva AM, Harris E, Crowe J, and Lok S. A human antibody that locks dengue virus E protein dimers prevents antibody-enhanced severe disease.  Science. In Press.
  12. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng T-S, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM. 2015. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. 2015 Nature Communications. 6:6341.
  13. Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM (2015) Preexisting Neutralizing Antibody Responses Distinguish Clinically Inapparent and Apparent Dengue Virus Infections in a Sri Lankan Pediatric Cohort. Journal of Infectious Diseases 211: 590-599.
  14. Wahala W, de Silva A, Gubler D, Ooi E, Vasudevan S, Farrar J (2014) Dengue virus neutralization and surrogates of protection. Dengue and dengue hemorrhagic fever: 577-589.
  15. Tissera H, Amarasinghe A, De Silva AD, Kariyawasam P, Corbett KS, Katzelnick L, Tam C, Letson GW, Margolis HS, de Silva AM (2014) Burden of dengue infection and disease in a pediatric cohort in urban Sri Lanka. The American journal of tropical medicine and hygiene 91: 132-137.
  16. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE (2014) Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. Journal of virology 88: 12233-12241.
  17. Liu P, Wang X, Itano MS, Neumann AK, de Silva AM, Jacobson K, Thompson NL (2014) Low Copy Numbers of DC‐SIGN in Cell Membrane Microdomains: Implications for Structure and Function. Traffic 15: 179-196.
  18. Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE and Lok S. (2014) A potent anti‐dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO molecular medicine: e201303404.
  19.  de Alwis R, Williams KL, Schmid MA, Lai C-Y, Patel B, Smith SA, Crowe JE, Wang W-K, Harris E, de Silva AM (2014) Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera. PLoS pathogens 10: e1004386.
  20. de Alwis R, de Silva AM (2014) Measuring Antibody Neutralization of Dengue Virus (DENV) Using a Flow Cytometry-Based Technique. Dengue: Springer New York. pp. 27-39.
  21. Zhou Y, Austin SK, Fremont DH, Yount BL, Huynh JP, de Silva AM, Baric RS, Messer WB (2013) The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology 439: 57-64.
  22. White LJ, Sariol CA, Mattocks MD, MPB WW, Yingsiwaphat V, Collier ML, Whitley J, Mikkelsen R, Rodriguez IV, Martinez MI (2013) An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. Journal of virology 87: 3409-3424.
  23. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, Mattia KA, Doranz BJ, Grey HM, Shresta S, Peters B, Sette A. (2013) Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proceedings of the National Academy of Sciences 110: E2046-E2053.
  24. Tissera H, Amarasinge A, de Silva AM (2013) Surveillance of dengue in a community cohort in metropolitan Colombo, Sri Lanka: part I methods and study population. WHO Dengue Bull 37: 141-154.
  25. Tam CC, Tissera H, de Silva AM, De Silva AD, Margolis HS, Amarasinge A (2013) Estimates of dengue force of infection in children in Colombo, Sri Lanka. PLoS neglected tropical diseases 7: e2259.
  26. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE (2013) Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. Journal of Infectious Diseases 207: 1898-1908.
  27. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Crowe JE (2013) The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 4: e00873-00813.
  28. Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Wahala W, de Silva AM, Swaminathan S, Khanna N. (2013) Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without Pre-membrane protein and induces high titer neutralizing antibodies. PloS one 8: e64595.
  29. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12-20.
  30. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, de Silva AM  (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proceedings of the National Academy of Sciences 109: 7439-7444.